Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, Kusnierczyk A, Slupphaug G, Standal T, Waage A, Slørdahl TS, Rø TB, Rustad E, Sundan A, Hay C, Cooper Z, Schuller AG, Woessner R, Borodovsky A, Menu E, Børset M, Sponaas AM. Yang R, et al. Among authors: woessner r. J Immunother Cancer. 2020 May;8(1):e000610. doi: 10.1136/jitc-2020-000610. J Immunother Cancer. 2020. PMID: 32409420 Free PMC article.
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity.
Borodovsky A, Barbon CM, Wang Y, Ye M, Prickett L, Chandra D, Shaw J, Deng N, Sachsenmeier K, Clarke JD, Linghu B, Brown GA, Brown J, Congreve M, Cheng RK, Dore AS, Hurrell E, Shao W, Woessner R, Reimer C, Drew L, Fawell S, Schuller AG, Mele DA. Borodovsky A, et al. Among authors: woessner r. J Immunother Cancer. 2020 Jul;8(2):e000417. doi: 10.1136/jitc-2019-000417. J Immunother Cancer. 2020. PMID: 32727810 Free PMC article.
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.
Sidders B, Zhang P, Goodwin K, O'Connor G, Russell DL, Borodovsky A, Armenia J, McEwen R, Linghu B, Bendell JC, Bauer TM, Patel MR, Falchook GS, Merchant M, Pouliot G, Barrett JC, Dry JR, Woessner R, Sachsenmeier K. Sidders B, et al. Among authors: woessner r. Clin Cancer Res. 2020 May 1;26(9):2176-2187. doi: 10.1158/1078-0432.CCR-19-2183. Epub 2020 Jan 17. Clin Cancer Res. 2020. PMID: 31953314 Clinical Trial.
Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.
Voronova V, Peskov K, Kosinsky Y, Helmlinger G, Chu L, Borodovsky A, Woessner R, Sachsenmeier K, Shao W, Kumar R, Pouliot G, Merchant M, Kimko H, Mugundu G. Voronova V, et al. Among authors: woessner r. Front Immunol. 2021 Mar 2;12:617316. doi: 10.3389/fimmu.2021.617316. eCollection 2021. Front Immunol. 2021. PMID: 33737925 Free PMC article.
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. Reilley MJ, et al. Among authors: woessner r. J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5. J Immunother Cancer. 2018. PMID: 30446007 Free PMC article. Clinical Trial.
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Proia TA, Singh M, Woessner R, Carnevalli L, Bommakanti G, Magiera L, Srinivasan S, Grosskurth S, Collins M, Womack C, Griffin M, Ye M, Cantin S, Russell D, Xie M, Hughes A, Deng N, Mele DA, Fawell S, Barry S, Reimer C, Barrett JC, McCoon P. Proia TA, et al. Among authors: woessner r. Clin Cancer Res. 2020 Dec 1;26(23):6335-6349. doi: 10.1158/1078-0432.CCR-20-1066. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943458
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Kuhn DJ, et al. Among authors: woessner r. Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29. Blood. 2012. PMID: 22932796 Free PMC article.
Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.
Su Q, Banks E, Bebernitz G, Bell K, Borenstein CF, Chen H, Chuaqui CE, Deng N, Ferguson AD, Kawatkar S, Grimster NP, Ruston L, Lyne PD, Read JA, Peng X, Pei X, Fawell S, Tang Z, Throner S, Vasbinder MM, Wang H, Winter-Holt J, Woessner R, Wu A, Yang W, Zinda M, Kettle JG. Su Q, et al. Among authors: woessner r. J Med Chem. 2020 May 14;63(9):4517-4527. doi: 10.1021/acs.jmedchem.9b01392. Epub 2020 Apr 28. J Med Chem. 2020. PMID: 32297743
107 results